GRM2 and Alzheimer disease: However, it suggests that selective activators (agonists or positive allosteric modulators) of mGluR3 but not the non-selective mGluR2/3 activators are a viable strategy to reverse Aβ-triggered pathology in both astrocytes and microglia and slow AD progression.